A B S T R A C T The atherogenic mechanism of homocystinemia has been defined by measuring endothelial cell loss and regeneration, platelet consumption, and intimal lesion formation in a primate model. Three groups of baboons were studied: (a) 8 control animals; (b) 15 animals after 3 mo of continuous homocystinemia; and (c) 11 animals after 3 mo of combined homocystinemia and oral treatment with dipyridamole.
INTRODUCTION
Lesions of atherosclerosis, identical to those found in man, are readily produced in the subhuman primate Received for publication 18 December 1975 and in revised form 15 April 1976. (1-4). Intimal proliferative smooth muscle cell lesions, identical in appearance to the fibromusculoelastic lesion considered to be the precursor of atherosclerosis in man, are transiently produced in the arteries of nonhuman primates by a variety of methods including mechanical deendothelialization (5) (6) (7) (8) . Furthermore, the addition of a fatty diet, either alone or in combination with mechanical injury, can produce the classic lesions of atherosclerosis, the fatty streak and the fibrous plaque (9, 10) . The genesis of these lesions may involve: (a) endothelial injury leading to focal desquamation of cells; (b) adherence and aggregation of platelets to exposed subendothelial connective tissue; (c) local release of platelet constituents, including a platelet mitogenic factor (11) , and passage of plasma constituents into the underlying artery wall; (d) migration of smooth muscle cells through fenestrae of the internal elastic lamina into the intima and platelet-mediated intimal proliferation of smooth muscle cells; (e) formation of connective tissue matrix by the smooth muscle cells through synthesis and secretion of collagen, elastic fiber proteins, and glycosaminoglycans; and (f) intracellular and extracellular lipid accumulation. Maximal lesion formation occurs within 3 mo after mechanical injury. The lesions appear to regress once the overlying endothelium has regenerated, and resolution is virtually complete 3 mo later in normocholesterolemic monkeys (6) . This formulation suggests that repeated or chronic endothelial cell loss may be the first event leading to atherosclerosis.
In this study we test the proposition that chronic, chemically induced endothelial cell injury produces arteriosclerosis through platelet-mediated intimal proliferation of smooth muscle cells and that drug-induced platelet dysfunction is capable of preventing the smooth muscle proliferative response.
The Journal of Clinical Investigation Volume 58 September 1976 -731-741 METHODS Baboon homocystine vascular model. 34 normal male baboons (Papio cynocephalus) were studied: 8 controls, 15 chronic homocysteine infusion animals, and 11 animals receiving both chronic homocysteine infusions and dipyridamole. The animals weighed 10-12 kg and had hematocrits of 40±3%o, leukocyte counts of 5,000±1,200/,pl, and platelet counts of 279,000+59,000/,l. They were free of tuberculosis, dewormed, and observed to be disease-free for at least 6 wk before use. To facilitate continuous intravenous infusion and repeated blood sampling, the animals were maintained in restraining chairs during the period of observation. In addition, a femoral arteriovenous Silastic shunt was used, 0.24 cnm internal diameter and 25 cm in length, with Dacron sewing cuffs at skin exit sites (12) (13) (14) .
A solution of l-homocysteine (Aldrich Chemical Co., Inc., Milwaukee, Wis.) or a control solution alone was infused continuously by femoral AV shunt throughout a 3-mo period using a roller infusion pump (Holter pump, model 921, Extracorporeal Medical Specialties, Inc., King of Prussia, Pa.) and a T-tube connector. 0.3 g of homocysteine per kg body weight was infused per day (3 g dissolved in 100 ml 0.15 M NaCl solution at pH 7.4 and sterilized by filtration). The homocysteine infusion was given at a rate of about 4 ml/h and produced plasma homocystine levels of 0.1-0.2 mM due to the endogenous transformation of homocysteine to homocystine. Homocystine concentrations were measured each week. Platelet and fibrinogen concentration, survival and turnover, were measured before and at monthly intervals during the infusion period. Plasma cholesterol levels were obtained before the infusion studies and before sacrifice.
Treatmentt. Dipyridamole was given orally to 11 animals throughout the 3-mo period of homocysteine infusion in doses of 30 mg/kg per day (in three divided doses). This dose, which is a threefold increase over that used in the acute studies (14) , was required to normalize the platelet consumption produced by the level of chronic homocystinemia used in this study.
Laboratory studies. Platelet counts were measured with an electronic particle counter on peripheral blood collected in EDTA by a previously described method (15, 16) . The mean platelet count of 50 normal baboons was 279,000± 59,000/pl (±1 SD). Platelet survival was determined from the disappearance of radioactivity from blood sampled 5-10 times after injection of autologous 51Cr-labeled platelets (14, 16) . In this procedure 100 ml autologous whole blood was collected directly into a plastic plasma pack (Fenwall TA-6, Fenwall Laboratories, Inc., Morton Grove, Ill.) containing 20 ml ACD anticoagulant, and centrifuged at 200 g for 10 min at room temperature. The supernatant, plateletrich plasma was transferred to a second transfer bag by a plasma extractor, and the pH was adjusted to 6.5 with 0.15 M citric acid (about 0.1 ml/10 ml plasma). Platelets were then formed into a pellet by centrifuging at 3,000 9 for 15 min. The supernatant plasma was removed except for 2-3 ml residual plasma into which the platelets were carefully resuspended. This platelet suspension was then incubated with 50 /LCi of radiochromium (New England Nuclear, Boston, Mass.) for 20 min. About 40 ml nonradioactive platelet-poor plasma and about 50 ml sterile air were then added, and the pellet reformed by centrifuging at 3,000 g for 15 min. The residual radioactive platelet-poor plasma was completely decanted without disturbing the pellet. 10 ml nonradioactive platelet-poor plasma was carefully layered over the platelet pellet and then discarded by decantation.
This maneuver washed the bag of more than 95% of the residual nonplatelet-bound 5"Cr. The presence of air in the bag facilitated this step by maintaining the overall configuration of the bag during decantation. The labeled platelet pellet was gently suspended in about 2 ml nonradioactive platelet-poor plasma. Contaminating erythrocytes were largely removed by a final slow centrifugation of 100 g for 5 min. A known amount of 51Cr-labeled platelet suspension was administered to the animal by intravenous injection after the preparation of a standard. 3-ml samples of whole blood, collected in EDTA twice daily for 3 days and daily for an additional 3 days, were lysed with 0.1 ml sodium dodecyl sulfate and counted for radioactivity in a gamma spectrometer (Nuclear-Chicago, Des Plaines, Ill.).
Platelet survival time was determined by computer least squares fitting to a gamma function as described by Paulus (17) and Mlurphy et al. (18) (19) (20) . The proportion of labeled platelets remaining within the systemic circulation after infusion (i.e., "recovery") was calculated from the platelet activity per milliliter extrapolated to zero time, multiplied by the estimated blood volume, and divided by the platelet 51Cr activity injected. Platelet consumption, measured as platelet turnover per microliter of blood per day, was calculated from the peripheral platelet count divided by the platelet survival time in days and corrected for recovery.
In 24 normal male baboons, platelet survival was 5.5±0.3 days. Platelet recovery averaged 85±5% and platelet turnover was 59,000±7,000 platelets/pl per day.
For calculating fibrinogen turnover, the concentration of fibrinogen was estimated by a spectrophotometric method in which the optical density of thrombin-clottable protein was determined after collection on a glass rod and subsequent solution in alkaline urea (21) . The fibrinogen concentration in 24 normal animals was 2.71±0.22 mg/ml. Labeling of normal fibrinogen with "2I was performed by the method of Takeda (22) . This technique involved repeated precipitation of fibrinogen with 257% ammonium sulfate saturation followed by dissolving the precipitate in 0.005 M sodium citrate, labeling with ['"I] Cl (monoiodochloride) and removal of unbound "I. The solution was maintained at 4°C for 1 h and then centrifuged at 20,000 g for 30 min at 4'C to remove any cryoprecipitable material. It was sterilized by filtration. In our preparations, the molar ratio of iodine to fibrinogen was always less than 0.25; the fibrinogen was 95 % clottable (range, 92-98%). For survival measurements sufficient labeled fibrinogen was prepared for several months use. Individual doses were flash frozen and stored at -85°C.
Survival did not change significantly during the time of storage. Fibrinogen survival, determined from the half-time disappearance and divided by the natural logarithm of 2, averaged 2.6±0.2 days in 24 normal animals. Fibrinogen turnover, used as a measure of fibrinogen consumption, was calculated from the concentration of plasma fibrinogen divided by its mean survival time. In 24 normal animals fibrinogen turnover averaged 1.00±0.10 mg/ml per day.
Platelet function was measured by bleeding time, glassbead retention test, and aggregation induced by ADP (0.5, 1.0, 1.5, 2.0, and 10.0 ,uM final concentration), collagen (5 ,g/ml), and epinephrine (2.5 Ag/ml). The bleeding time was measured by the standardized template technique (23), the mean value in 24 normal baboons was 4.0+1.2 min.
Platelet retention by glass-bead columns was measured by the Bowie modification of the Salzman method (24), blood being drawn by a two-syringe technique without anticoagulant and immediately passed through the standard column of beads by constant infusion at the rate of 2 ml/min. The delay between drawing and initiation of flow through the beads was less than 10 s. Platelet aggregation was estimated from changes in optical transmission of 0.02 M sodium citrated plasma at 37°C with a concentration of 300,000 platelets/pul (14, 25, 26) . Plastic equipment was used throughout, and plasma freshly drawn was kept at room temperature during the 30-70 min before testing.
Homocystine was quantified by column chromatography using a modified procedure of Spackman et al. (27) . Plasma samples were deproteinized by addition of an equal volume of 6%o sulfosalicyclic acid buffered to pH 2. Homocystine was separated on a 55-cm column of PA28 resin (Beckman Instruments, Inc., Palo Alto, Calif.) with use of 0.38 M sodium citrate buffer at pH 4.40. Temperature was maintained at 62°C with a buffer flow rate of 60 ml/h and the amino acid was eluted 62 min after addition of buffer. Homocystine is not detectable in the plasma of ncrmal animals.
Morphological procedures. Three types of vessel preparation were obtained: (a) lower abdominal aorta, iliac and femoral arteries for light and electron microscopic examination of lesion formation; (b) carotid arteries for [3H]thymidine incorporation by endothelial cells; (c) thoracic and upper abdominal aorta for silver stain quantitation of endothelial coverage. Specimens were obtained under general (halothane) anesthesia and assisted respiration in the following way. After opening the abdomen, the aorta and inferior vena cava were carefully freed by sharp dissection without affecting flow. The inferior vena cava was then cannulated to establish isolated venous drainage from the lower limbs and immediately thereafter the aorta was cannulated, flushed free of blood elements with 5%o glucose solution at 100 mm Hg of hydrostatic pressure, and perfusefixed with buffered half-strength Karnovsky's fixative (28) under 100 mm Hg pressure for 20 min in vivo. Once perfusion fixation of the distal arteries was underway, the carotid arteries were freed by sharp dissection, isolated, and carefully removed. The artery segments were gently flushed free of blood with saline, and excess adventitia removed for [3H]thymidine studies. Immediately after removing the carotid arteries, the chest was entered (thereby interrupting respiration), the arch of the aorta quickly cannulated, and drainage outflow was established above the renal arteries.
The aorta was then cleared of blood using 5% glucose solution at 100 mm Hg pressure. In vivo fixation was then carried out by perfusion-fixation of the thoracic and upper abdominal aorta with 0.3%o silver nitrate solution at a pressure of 100 mm Hg for 20 min (29) . After perfusionfixation, the vessels were removed by sharp dissection. The foregoingprocedure ensured the procurement of three different artery preparations from a single living animal while using isolated regional pressure-perfusion fixation.
Initimal lesion score. At the time of sacrifice the aorta was cannulated below the renal vessels, flushed free of blood with 5% glucose solution, and then perfuse-fixed with buffered half-strength Karnovsky's fixative (28) under 100 mm Hg hydrostatic pressure for 20 min in vivo. Vessels were subsequently removed by sharp dissection and placed in half-strength Karnovsky's fixative for 6 h at 4°C. Segments from abdominal aorta, and each iliac artery were removed for scanning electron micrographs. The remaining vascular tissues were subsequently cut into approximately 1-mm rings and returned to the fixative for another hour at 4°C. They were then washed in 0.1 M cacodylate buffer containing 0.2 M sucrose (pH 7.3) and subsequently postfixed in lgo osmium tetroxide buffered with s-collidine or with phosphate buffer (pH 7.3) for 11 h, followed by en bloc staining with 2% uranyl acetate for i h. After embedding in epoxy resin, 1-,um thick sections were cut as circles, and stained with a combination of basic fuchsin and azure II-methylene blue for light microscopy (30) .
Selected thin sections were cut at approximately 800 A thickness for transmission electron microscopy. These sections were stained with lead citrate followed by uranyl acetate. All of the sections for electron microscopy were examined in an AEI801 electron microscope (AEI Scientific Apparatus Inc., Elmsford, N. Y.).
Five random sections were prepared for each of five vessels (abdominal aorta, right and left iliac arteries, right and left femoral arteries) for light microscopic scoring of intimal lesions. The lesions were graded by two observers in a 'blind' manner according to the cell layer depth of intimal smooth muscle cells: grade 0-only occasional intimal smooth muscle cells; grade 1-1-5 cells deep; grade 2-6-10 cells; grade 3-11-15 cells; grade 4-16-20 cells; grade 5-> 20 cells deep. The overall score was calculated for each animal by summing the scores of all 25 sections examined (possible range of scores was 0-125).
[3H] Thymidine labelintg intdex. Both carotid arteries were removed by sharp dissection, flushed with saline, and cut into 20-mm lengths. Whole segments were placed in 3-4 ml medium TC 199 containing 1 /Ci ['H]thymidine/ml and incubated at 37°C for 4 h. The vessel segments were removed, trimmed, opened longitudinally, and mounted flat for fixing 24 h in 10%o neutral buffered formaldehyde (31) . The endothelium was prepared for autoradiography by the method of Schwartz and Benditt (32) which involved the following procedures. The luminal surface of the specimen was embedded in collodion onto a slide leaving the adventitial surface exposed. The adventitial surface was then embedded in gelatin and bonded to a gelatin-coated slide by fixation with formaldehyde while the specimen and the coated slide were held together under pressure. Subsequently the collodion overlying the endothelial cells was removed with ether and alcohol thereby exposing the luminal surface of endothelial cells for coating with autoradiographic emulsion. Autoradiography was performed by hand dipping endothelial mounts in Kodak NTB-2 emulsion, 2-wk exposure, followed by Kodak D-19 developer and rapid fixer (Eastman Kodak Co., Rochester, N. Y.). The preparations were stained with Harris' hematoxylin and mounted.
About 80%o of the mounts were complete, containing over 90%o of the endothelial cells intact and countable. All of the endothelial cells from each mount, i.e., 15,000 cells each, were scored as labeled or unlabeled, and the [3H]thymidine labeling index represented the ratio of these values expressed as a percentage.
Entdothelial cell loss. Pressure-perfusion fixation was carried out on the thoracic and upper abdominal aorta with 0.3%o silver nitrate solution at the time of sacrifice in vivo. The entire endovascular surface of whole-aorta mounts was then examined morphometrically by means of a grid micrometer, and the proportion of the surface not covered by endothelial cells was determined.
RESULTS
Endothelial cell inijury. Endothelial cell coverage was completely intact (Fig. la) in the eight control animals when the vessels were prepared by pressure-perfusion fixation in vivo using either 0.3% AgNO3 staining or scanning electron microscopy. Patchy endothelial cell '9~~~~~'-*** W~~- loss was observed in all animals made homocystinemic by continuous infusions of homocysteine (Fig. ib) . When viewed by scanning electron microscopy, platelets were found to accumulate at some sites of endothelial cell loss (Fig. 2) , although platelets were not regularly observed on the chronically denuded areas when prepared by silv,er staining for direct microscopic examination. The overall loss of aortic endothelium in the group of 15 homocystinemic animals averaged 9.6±2.2% 1 of the aortic surface and corresponded with a mean plasma homocystine concentration before sacrifice of 0.17±0.01 mM (Table I) an SD of slope and intercept of 7.205 and 1.359, respectively.
In the 11 homocystinemic animals treated with oral dipyridamole (30 mg/kg per day), 7.0+0.9% of the aortic endothelial cells was absent with a mean plasma homocystine concentration before sacrifice of 0.13±0.01 mM ( Table I ). The relationship between homocystine level and endothelial cell desquamation was not changed by dipyridamole treatment (P > 0.75).
Platelet consumption. Platelet survival in the homocystinemic animals was reduced to 2.8±0.3 days compared with 5.4±0.1 days in the control group (Table I) .
Reciprocally, platelet turnover was increased threefold in the homocystinemic animals, i.e., 183,000+17,000 platelets/isl per day compared with 63,000+4,000 platelets/,*l per day in the control group. Platelet survival times were related to the logarithm of the homocystine concentration (Fig. 4A ). r = 0.965, P < 0.001, and the regression line was represented by y = 0.453e'-'.
Determinations of platelet survival also correlated with the logarithm of aortic endothelial cell loss (Fig.  4B ). r = 0.958, P < 0.001, and the regression line was represented by y = 44.0ez'7.
Platelet survival times were significantly prolonged by dipyridamole treatment (4.8+0.2 days compared with 2.8±0.3 days, P < 0.001) despite continued homocystinemia ( Fig. 4A and 4B ). Platelet turnover was also returned to near normal values (Table I , P < 0.001).
In homocystinemic animals fibrinogen survival and turnover were not changed significantly from control values, i.e., 2.4±0.2 days and 1.2±0.2 mg/ml per day, respectively, compared with 2.5±0.2 days and 1.1 mg/ ml per day in control animals. Fibrinogen kinetics were not altered by dipyridamole treatment (2.4+0.2 days and 1.3±0.3 mg/ml per day, respectively).
Platelet aggregation to ADP, epinephrine, and collagen was not significantly different in six dipyridamole-treated animals compared with six untreated homocystinemic animals. Similarly, the bleeding time was not significantly prolonged by dipyridamole therapy (4.8+2.5 min compared with 4.2±2.0 min). However, dipyridamole treatment reduced platelet retention by glass-bead columns from 43±12% retained in homocystinemic animals to 26±9% in treated animals (P <0.05).
Endothelial cell regeneration. In control animals the ['H]thymidine-labeling index of endothelial cells averaged 0.0011+0.0001%. Animals with induced homocystinemia showed a greater than 25-fold increase in the endothelial cells incorporating ['H]thymidine, i.e., 0.0296+0.0087%, P < 0.001. Dipyridamole-treated animals had a 15-fold increase in [3H]thymidine-labeling index (0.0162±0.0051%, P < 0.001).
Intimal lesion formation. For every animal studied, five random sections from each of five different arteries were graded 0-5 (see Methods). Single intimal smooth muscle cells were occasionally observed in control animals ( Fig. 5 , scores averaged 4±1, range 1-9).
All of the homocystinemic animals developed eccentric fibromusculoelastic lesions (Fig. 6) . the homocystinemic animals averaged 63+5, range 35- 98 (Table II) . The lesion score correlated directly with the overall mean homocystine concentration (Fig. 8 ). r = 0.956, P < 0.001, and the regression line was y= 0.375x-12.7. 
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t Different from controls at P < 0.001.
The fine structure of the lesions (Fig. 9 ) was typical of early lesion formation similar to the fibromusculoelastic lesions in man (9) . They demonstrated the presence of numerous smooth muscle cells surrounded by large amounts of small collagen fibers and elastic fibers rich in microfibrils, suggesting that the elastic fibers were relatively immature (33) . In many regions the luminal surface of the lesions had no endothelial cell cover, while in other regions cells appeared to be in the process of attempting to cover the surface.
Effect of dipyridamole on intimal lesion formation. In the group of 11 animals receiving oral dipyridamole throughout the 3-mo period of homocystinemia, the mean intimal lesion score was 16±2 (range 7-25), compared with 4±1 in control animals and 63±5 in untreated homocystinemic animals ( Figs. 7 and 8 , Table  II ). The difference in the intimal lesion scores between the dipyridamole-treated and untreated homocystinemic 0 FIGURE 7 A light micrograph of a segment of the iliac artery of a homocystinemic-dipyridamole treated animal (cf. Figs. 5 and 6 ). It can be seen that the intima is nearly as thin as that of the control animal, and that the media and adventia are both visible in this micrograph in comparison with the markedly thickened intima demonstrated in the homocystinemic animals in Fig. 6 . Magnification x 220. 8 The formation of intimal smoot and endothelial cell desquamation. A linear observed between the intimal proliferative the loss of aortic endothelial cells (0). significance of P <0.001. The regression sented by y = 0.375x-12.7. Dipyridamole markedly reduced the intimal lesion score animals was significant at P < 0.001. TI sponded with the dipyridamole interrup consumption but was observed despite aortic endothelial cells (Table I ). The score in the dipyridamole-treated anima however, also significantly greater than mals (P < 0.01).
Serum cholesterol concentrations fo homocystinemic, and treated group wert 96+6, respectively. No correlation was ol animals between cholesterol levels an( scores or the presence of lipid within tl
DISCUSSION
The effects of homocystine. This stuc to clarify the mechanism responsible fo accelerated atherosclerosis found in patiei homocystinemia. The clinical syndrome uria, an inborn deficiency of cystathion characterized by atherosclerotic occlusior cerebral, renal, and pulmonary arteries, in fatal infarction before the 3rd decade It has been reported on the basis of taneous injection of homocystine into ral cystine stimulates the synthesis of conne ments in the artery wall. These studies, been difficult, to reproduce presumably lack of continuous homocystinemia (40--In an earlier acute study continuous cystinemia in primates was shown to inc of arterial endothelium (14) . The preset strates that homocystinemia maintained duces sustained endothelial cell loss in p: level of plasma homocystine when the concentration exceeds about 0.06 mM (Fig. 3) . The inability to detect measurable deficiencies in endothelial cell coverage at lower homocystine concentrations may be explained by compensatory coverage achieved by increased endothelial regeneration (Table I) .
Although we find no evidence to implicate hypercholesterolemia or hypertriglyceridemia in homocystineinduced lesions, the importance of lipids in the genesis of atherosclerosis has long been emphasized (4) but poorly understood. Clearly, lipid accumulation, both within the smooth muscle cells and in the surrounding matrix, is important in preventing lesion regression 80 160 (10) . Both the smooth muscle cells and the matrix proteoglycans they form have a marked affinity for lipo-:h niuscle lesions proteins (43) . Of equal interest are observations sugrelationship was gesting that chronic (9 mo or longer) sustained hyperlesion score and cholesterolemia will result in endothelial "injury" and r = 0.956, with focal denudation similar to that observed in the homotrne watm rent e ( cystinemic animals in the present study (44) . Thus, (Pt<0.001). lipids may exert in part a similar effect to that seen in homocystinemia.
tis effect corre-The role of platelets in lesion formation. Platelets tino platseet ofaccumulate on exposed subendothelial connective tissue .t .abse .o surface by adhesion and aggregation to form platelet 1 (Finial 7e)sin thrombi (45) (46) (47) (48) . Adherent platelets undergo the rei s (Fig .7) 'is lease reaction as evidenced morphologically by degranulation (6, (45) (46) (47) (48) (49) (50) (51) . At least one constituent released from r the control, platelets is a mitogenic factor that stimulates the pro-99±6, 106+7, liferation of smooth muscle cells (11) . This platelet bseredi the factor was initially discovered from the observation that dsterved intesen arterial smooth muscle cells in culture neither synthesize ether lesions.
DNA nor divide in medium containing serum made hie lesions.
from platelet-free plasma. In contrast, medium containing whole blood serum, or platelet-free plasma serum containing a supernate derived from exposure of a ly was designed plasma-free preparation of platelets to purified thromry bin, are identical in their ability to elicit a mitogenic its with chronic ofs with chronic response from the cells ( 11 ) .
Of homocystin-
The present studies provide in vivo evidence that of myocardia platelets are important in the process of arteriosclerosis oft Yocaredial, by demonstrating that platelet consumption correlates oftn rsulting with intimal lesion formation and that the interruption of life (34) (35) (36) (37) (38) (39) . of platelet consumption using a known inhibitor of repeated subcuplatelet function prevents lesion formation. Interestingly, )bits that homodirect morphology evidences only minimal platelet accumulation at sites of chronic endothelial loss which is hbe e of the also in accord with the late findings after mechanical 42). desquamation (46, 48) . antiplatelet serum. Similarly, Friedman and Stemmer-are secretory products of the proliferating smooth man (personal communication) prevented balloon cathe-muscle cells (55, 56) . This lesion is characteristic of ter-induced lesion formation by severe thrombocyto-arteriosclerosis. The intraand extracellular accumulapenia. And finally, a retrospective study in pigs affected tions of lipid by intimal smooth muscle cells and conwith von Willebrand's disease, a genetic defect in plate-comitant formation of connective tissue appear to be let-surface interaction (53) , reported a reduced fre-facilitated by disruption of the endothelial cell barrier quency of atherosclerosis in the adult animals (54) . and exposure of the artery wall to platelets and plasma The intimal proliferative smooth muscle lesion con-factors. tains the connective tissue matrix components of elastic Role of antiplatelet agents. Inhibition of platelet adfibers, collagen, and glycosaminoglycanii, all of which hesion, aggregation, and release are variably produced by a wide variety of pharmacologic agents (50, 51, (57) (58) (59) . These include a group of nonsteroidal anti-inflammatory drugs such as acetylsalicylic acid and sulfinpyrazone. Although their mode of action has not yet been fully determined, these drugs characteristically inhibit the platelet release reaction and the secondary phase of ADP or epinephrine-induced aggregation with little or no effect on primary ADP aggregation. These drugs appear to be less useful for interrupting adhesion-related effects, e.g., acetylsalicylic acid fails to reduce the adhesion and degranulation of platelets to subendothelium (53) . Correlation between in vitro effects on platelet function tests and in vivo antithrombotic effects is variable. For example, in man treatment with sulfinpyrazone normalizes platelet survival and reduces thrombus formation without showing any measurable effect on in vitro tests of platelet function (60) .
A second group of drugs, the pyrimido-pyrimidine compounds, inhibits both primary and secondary ADPor epinephrine-induced aggregation and platelet release, aggregation induced by thrombin or collagen, and platelet retention by glass-bead columns. These drugs appear to affect platelet cAMP by enhancing adenylcyclase and inhibiting phosphodiesterase activity (50, 51, (57) (58) (59) . Included in this class of agents is dipyridamole. Interestingly, dipyridamole interrupts platelet consumption and thromboembolism in man at concentrations that do not effect platelet function tests in vitro (61, 62) . This discrepancy between in vivo and in vitro effects is further evidenced by a recent comparison of in vivo and in vitro collagen-induced platelet aggregation that showed the inhibitory effect of dipyridamole in vivo to be enhanced many times over that observed in vitro (63) .
Consideration must be given to the possibility that dipyridamole may have produced its beneficial effect on lesion formation by protecting the endothelium from injury, by modifying the thrombogenicity of the subendothelium, or by inhibiting the proliferation of smooth muscle cells. The data in Table I and Fig. 1 indicate that homocystine-induced endothelial cell loss remained quantitatively unchanged by dipyridamole therapy. The drug therefore appears to have no protective effect on the endothelium. Furthermore, smooth muscle cell proliferation also appears to be unaffected because smooth muscle cells proliferate normally in culture with dipyridamole concentrations as great as 10 M (unpublished observation). Since the only measurable effect of dipyridamole appears to be on platelet consumption, we conclude that the drug effect is mediated through plateletrelated mechanisms. Our observation that dipyridamoletreated animals show reduced platelet retention by glassbead columns suggests that the effect involves pharmacologic inhibition of platelet function rather than some alteration of the subendothelial surface.
On the basis of these studies we conclude that sustained chemically induced endothelial cell injury results in endothelial cell loss followed by platelet adherence and release and the development of progressive intimal arteriosclerotic lesions. The fundamental role of platelets in the genesis of these lesions is demonstrated by the capacity of an inhibitor of platelet function to prevent intimal smooth muscle proliferation, and consequent lesion formation. These observations imply potential therapeutic benefit of antiplatelet drugs in the prevention or interruption of atherogenesis in man.
